Japanese Simple Chinese Traditional Chinese Korean 

Conference Menu

Current Event 

Day 1
Day 2
Day 3
PDF Download
Short Course
Delegate List
Hotel & Travel
Sponsor & Exhibits
Press Pass 
Request Brochure 

Chemical Computing Group 



Reaction Biology 


Vlife Logo 

Intelligent Pharma 



Insight Pharma Reports 

Science AAAS logo 

The Scientist 

chemical biology 



Markets and Markets logo 

Reports and Reports 

CanBiotech logo 



Pharm Cast 

SelectScience logo 


Therapeutic Target Space:
Methods for Druggability Assessment

Final Days to Register! 

Cambridge Healthtech Institute’s Eleventh Annual Structure-Based Drug Design conference brings to focus the latest development in computational technology for drug discovery, and puts structure-based molecular approaches into the perspective of targeted therapeutics.

Conference Highlights: 

  • Protein Flexibility
  • Fully Synthetic Protein-Protein Interaction Inhibitor
  • Fragment-to-Lead Optimization
  • High Performance Computing and Collaborative Drug Design
  • State-of-the-Art Molecular Dynamics Simulations


Keynote Speaker: 

Millisecond-Long Molecular Dynamics Simulations of Proteins on a Special-Purpose Machine

David ShawDavid E. Shaw, Ph.D., Chief Scientist, D. E. Shaw Research

David E. Shaw serves as chief scientist of D. E. Shaw Research and as a senior research fellow at the Center for Computational Biology and Bioinformatics at Columbia University. He received his Ph.D. from Stanford University in 1980, served on the faculty of the Computer Science Department at Columbia until 1986, and founded the D. E. Shaw group in 1988. Since 2001, Dr. Shaw has devoted most of his time to hands-on research in the field of computational biochemistry. His lab is currently involved in the development of new algorithms and machine architectures for high-speed molecular dynamics simulations of biological macromolecules, and in the application of such simulations to basic scientific research and computer-assisted drug design.

Dr. Shaw was appointed to the President’s Council of Advisors on Science and Technology by President Clinton in 1994, and again by President Obama in 2009. He is a fellow of the American Academy of Arts and Sciences and of the American Association for the Advancement of Science.

PodcastAnton: Molecular Dynamics Simulation for Drug Design 



Dinner Short Course: 

June 8, 2011


Identification of Druggable Sites for Protein-Protein Interaction Targets 


Scientific Advisory Board: 

José Duca, Ph.D., Head, Computer Aided Drug Discovery, Novartis 

Alan C. Rigby, Ph.D., Vice President, Research, Computational Discovery, ImClone Systems-A wholly-owned subsidiary of Eli Lilly and Company 

Tomi Sawyer, Ph.D., CSO, Aileron Therapeutics, Inc.; Editor-in-Chief, Chemical Biology & Drug Design 

Woody Sherman, Ph.D., Vice President, Applications Science, Schrödinger, Inc. 

Gergely Toth, Ph.D., Research Fellow, Department of Chemistry, University of Cambridge 

Marcel Verdonk, Ph.D., Director, Computational Chemistry and Informatics, Astex Therapeutics Ltd. 

Pat Walters, Ph.D., Senior Research Fellow, Vertex Pharmaceuticals, Inc. 

Chris Williams, Ph.D., Principal Scientist, Chemical Computing Group 


Co-Located With:
Next-Gen Kinase Inhibitors